Azzad Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-5,810
Closed -$416K 306
2017
Q4
$416K Sell
5,810
-16,737
-74% -$1.27M 0.13% 219
2017
Q3
$1.83M Buy
22,547
+655
+3% +$50.1K 0.61% 43
2017
Q2
$1.55M Buy
21,892
+1,222
+6% +$81.3K 0.56% 44
2017
Q1
$1.4M Buy
20,670
+1,600
+8% +$113K 0.53% 54
2016
Q4
$1.37M Buy
19,070
+691
+4% +$51.4K 0.56% 55
2016
Q3
$1.45M Buy
18,379
+3,632
+25% +$295K 0.6% 51
2016
Q2
$1.23M Buy
14,747
+2,154
+17% +$191K 0.52% 66
2016
Q1
$1.16M Buy
12,593
+817
+7% +$73.7K 0.51% 66
2015
Q4
$1.19M Buy
11,776
+1,049
+10% +$109K 0.57% 50
2015
Q3
$1.05M Buy
10,727
+1,023
+11% +$114K 0.56% 57
2015
Q2
$1.14M Buy
9,704
+921
+10% +$101K 0.57% 52
2015
Q1
$862K Buy
8,783
+4,212
+92% +$428K 0.41% 104
2014
Q4
$431K Buy
4,571
+251
+6% +$26K 0.23% 176
2014
Q3
$460K Buy
4,320
+196
+5% +$19.2K 0.27% 150
2014
Q2
$342K Buy
4,124
+26
+0.6% +$2.02K 0.21% 208
2014
Q1
$290K Buy
4,098
+281
+7% +$22K 0.19% 221
2013
Q4
$287K Buy
3,817
+322
+9% +$22.4K 0.21% 200
2013
Q3
$220K Hold
3,495
0.18% 211
2013
Q2
$220K Buy
+3,495
New +$182K 0.19% 208

Other funds holding GILD

Azzad Asset Management's GILD Position: Q1 2018 in Review

Azzad Asset Management sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 5,810 shares — an estimated $416K sold.

Azzad Asset Management first reported a position in GILD in Q2 2013 and held it in 19 quarters. The position peaked at $1.83M in Q3 2017. 1,563 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

  • Azzad Asset Management reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
  • Azzad Asset Management sold 5,810 Gilead Sciences shares in Q1 2018, an estimated $416K.
  • Azzad Asset Management first reported a position in Gilead Sciences in Q2 2013 and held it in 19 quarters.
  • Azzad Asset Management's Gilead Sciences position peaked at $1.83M in Q3 2017.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on Azzad Asset Management's 13F filing for Q1 2018, filed 3 Apr 2024.